Brand name: Celebrex
Public Citizen has been assessing the quality and efficacy of drugs and devices since its founding in 1971. We use the law, petitions, and letters to monitor the FDA and coax the agency into action. Our actions have contributed to many drugs being pulled off the market. Public Citizen has also been instrumental in getting “black box” and other warnings on drugs. Our advocacy work on this drug is available below.
If you are interesting in reading our evaluations of the safety and efficacy of medications as well as information on drug side effects and interactions, please visit WorstPills.org.
More Information on Celecoxib (Celebrex)
- Letter Concerning Pfizer's Television Advertisement for Celebrex, April 9, 2007
- Statement: Valdecoxib (Bextra) ban a good step, but FDA Should pull Celecoxib (Celebrex) too, April 7, 2005
- Letter in the New York Times on Cox-2 Painkillers: Painkillers and Terrorism, February 19, 2005
- Testimony on the Dangers of Cox-2 Drugs, February 17, 2005
- Petition to Remove the COX-2 Inhibitors Celecoxib (Celebrex) and Valdecoxib (Bextra) from the Market, January 24, 2005
- Letter Revealing Heart Dangers in an Unpublished Clinical Trial of Celecoxib (Celebrex), January 31, 2005
- USA Today Editorial: Take Drugs off the Market, December 27, 2004
- Statement on FDA's Announcement About Use of Celecoxib (Celebrex) and Valdecoxib (Bextra), December 23, 2004
- Letter on Ethical Concerns with the “Alzheimer’s Disease Anti-Inflammatory Prevention Trial” (ADAPT), September 4, 2002
- Testimony on Celecoxib (Celebrex) and Rofecoxib (Vioxx), February 7-8, 2001
- Statement on Celecoxib (Celebrex), December 1, 1998